ns-018
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01423851)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1- Mol. weight
- 389.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4303389 ↗
- ChEMBLCHEMBL3545217 ↗
Also known as
- ns-018
- ns-018
- ns-018
- ns-018
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04854096 | Phase 2 | Mar 1, 2022 | Nippon Shinyaku Co Ltd |
| NCT01423851 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2011 | Nippon Shinyaku Co Ltd, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nippon Shinyaku Co Ltd | For profit | 2 | 2 | 1 | 2011 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1